Market Place
Sourcing Support
Ascletis Advances ASC30-ASC39 Combo for Clinical Trials
07 Apr 2026 //
PR NEWSWIRE
Ascend Pharma`s ASC39 Shows Eloralintide-Like Amylin Selectivity
17 Mar 2026 //
PR NEWSWIRE
Ascletis Eyes Quarterly GLP-1 Dosing Following Phase 2 Readout
10 Mar 2026 //
FIERCE BIOTECH
Ascletis Reports Positive Phase II Results of ASC30 for Obesity
10 Mar 2026 //
PR NEWSWIRE
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36
10 Feb 2026 //
PR NEWSWIRE
Sagimet Announces Positive 52-Wk Denifanstat Data in Severe MASH
02 Feb 2026 //
GLOBENEWSWIRE
Ascletis Reports Positive Phase III Results For Denifanstat
29 Jan 2026 //
PR NEWSWIRE
Ascletis to Develop ASC37 Triple Agonist
20 Jan 2026 //
PR NEWSWIRE
Ascletis Reports Positive U.S. Phase I Results For ASC50, IL-17
15 Dec 2025 //
PR NEWSWIRE
Ascletis Accepts Denifanstat NDA For Moderate To Severe Acne
10 Dec 2025 //
GLOBENEWSWIRE
Ascletis reports 7.7% weight loss for oral GLP-1 contender
08 Dec 2025 //
PR NEWSWIRE
Ascletis Selects ASC37: First Oral Triple Agonist
30 Nov 2025 //
PR NEWSWIRE
Ascletis Unveils Once-Monthly ASC36/ASC35 Coformulation
13 Nov 2025 //
PR NEWSWIRE
Ascletis Unveils Comprehensive Results Of ASC30 Studies
05 Nov 2025 //
PR NEWSWIRE
Ascletis Chooses ASC36, A Monthly Subcutaneous Amylin Agonist
30 Oct 2025 //
PR NEWSWIRE
Ascletis Finishes U.S. Phase IIa Enrollment in ASC30 for Obesity
20 Oct 2025 //
PR NEWSWIRE
Ascletis Selects Once-Monthly GLP-1R/GIPR Peptide ASC35
13 Oct 2025 //
PR NEWSWIRE
Ascletis Reveal ASC47 with Semaglutide, 56.2% More Weight Loss
21 Sep 2025 //
PR NEWSWIRE
Ascletis to Present Denifanstat Phase 3 Acne Results at EADV
17 Sep 2025 //
GLOBENEWSWIRE
Ascletis` GLP-1R Agonist ASC30 Shows 75-Day Half-Life in Study
09 Sep 2025 //
PR NEWSWIRE
Ascletis to Share 28-Day ASC30 Study Results at 61st EASD Meeting
02 Sep 2025 //
PR NEWSWIRE
Ascletis` ASC47 & ASC31 Combo Shows Greater Weight Loss in Model
17 Aug 2025 //
PR NEWSWIRE
Ascletis Enrolls Participants in U.S. Phase IIa Study for ASC30
06 Aug 2025 //
PR NEWSWIRE
Ascletis: Denifanstat Ph 3 in Acne Meets Endpoints
03 Jun 2025 //
PR NEWSWIRE
Ascletis sees no benefit to high, fast oral GLP-1 dose titration
23 Apr 2025 //
FIERCE BIOTECH
Ascletis Reports Positive U.S. Phase Ib Results of ASC30
22 Apr 2025 //
PR NEWSWIRE
Ascletis Reports Positive Interim Results from U.S. Phase Ib Trial
31 Mar 2025 //
PR NEWSWIRE
Ascletis Reports Positive Phase Ia Results For GLP-1R Agonist ASC30
21 Jan 2025 //
PR NEWSWIRE
Ascletis Announces ASC47 for Obesity with Superior Weight Loss
18 Dec 2024 //
PR NEWSWIRE
Ascletis Enters Obesity Drug Space With Phase I Trials Of GLP-1R Agonist ASC30
17 Sep 2024 //
PR NEWSWIRE
Ascletis Announces Completion of Enrollment of Patients in PIII Trial of ASC40
25 Sep 2023 //
PR NEWSWIRE
Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index
27 Feb 2023 //
PR NEWSWIRE
Ascletis doses subjects in first cohort of Covid-19 oral therapy trial
16 Jan 2023 //
CLINICAL TRIALS ARENA
